Free Newsletter
Study examines cost-effectiveness of Gardasil
A new study in the New England Journal of Medicine questions the cost-effectiveness of Gardasil in older women, saying that the payback is reduced by their increased exposure to the virus that causes cervical cancer. But the team of researchers from Harvard School of Public Health also confirmed that the vaccine is cost-effective among pre-adolescent girls because of their reduced exposure to the virus. Merck, which makes the vaccine and markets it around the world, quickly disputed the study, saying that its own economic models indicate that the vaccine provides a real payback when used for women.
The discussion over cost-effectiveness in the older age bracket is critical for Merck, which wants to expand the use of the cervical cancer vaccine. That expanded use is key to the company's efforts to gain more revenue from the vaccine. It's also an important discussion for GlaxoSmithKline, which has been commercializing Cervarix in various markets and working to gain an FDA approval.
--read the report in the Wall Street Journal
Related Articles:
Will Gardasil special help Merck?
Merck marketing role in Vioxx study
Gardasil side effects prompt CDC study
CDC details side effects reported on Gardasil
Gardasil: Some good news for Merck
Comments
I guess the study published earlier this week about Merck seeding studies on Vioxx is irrelevant here.......?????!!!!
- reply
Post new comment
Paid Research Reports
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
- Innovative Drug Discovery in Emerging Markets
- Market Opportunities for Supergenerics
- The Future of In Vitro and In Vivo Diagnostic Integration
SHARE
WITH: